ReviewDrugs2008
Treatment options for multidrug-resistant Acinetobacter species.
Review in Drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 59 citations in OpenAlex.
- Treatment effectiveness of antibiotic therapy in Veterans with multidrug-resistantAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Article
- Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.Antimicrobial agents and chemotherapy · 2016Article
- Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
- Laboratory evaluation of different agar media for isolation of carbapenem-resistant Acinetobacter spp.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014Article
- Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method.Journal of clinical microbiology · 2014Article
- Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes.Antimicrobial agents and chemotherapy · 2013Article
- Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands.Antimicrobial agents and chemotherapy · 2013Article
- The Acinetobacter baumannii group: a systemic review.World journal of emergency medicine · 2013Review
- Laboratory evaluation of the ESwab transport system for the recovery of carbapenem-resistant Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Article
- Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan.Antimicrobial agents and chemotherapy · 2011Article
- Synergistic effects between conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents.Antimicrobial agents and chemotherapy · 2010Article
- Acinetobacter pneumonia: Is the outcome different from the pneumonias caused by other agents.Annals of thoracic medicine · 2010Article
- Novel treatment approach to combat an infection with Acinetobacter.Proceedings (Baylor University. Medical Center) · 2010Article
- Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant Acinetobacter spp. are emerging nosocomial pathogens and have become a leading cause of Gram-negative infections in many parts of the world. Acinetobacter spp. are commonly implicated in bloodstream infection, hospital-acquired pneumonia, and wound and other surgical-site infections. They are difficult to treat, thus often leading to adverse patient outcome. Group II carbapenems (imipenem/cilastatin and meropenem) are the agents of choice for the treatment of severe infections caused by Acinetobacter spp. isolates susceptible to this antimicrobial group, but infection with carbapenem-resistant strains is increasingly encountered. Therapy of such infections necessitates the use of old drugs (e.g. colistin), unusual drugs (e.g. sulbactam) or drugs with which there is presently little clinical experience (e.g. tigecycline). Case reports, case series and small comparative observational studies suggest that these regimens are efficacious and demonstrate lower-than-expected toxicity, but there is substantial variation between these reports. Combination antimicrobial therapy is often used to treat infections caused by such multidrug-resistant strains. This article summarizes the cumulative experience with and the evidence for treating infections caused by multidrug-resistant Acinetobacter spp. infections. Special emphasis is placed on the use of 'non-traditional' antimicrobial agents, various aspects of combination therapy, alternative routes of drug administration, and discrete entities such as ventilator-associated pneumonia and postsurgical meningitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.